EKTAY
Price
$5.26
Change
+$0.09 (+1.74%)
Updated
May 13 closing price
Capitalization
3.09B
RCEL
Price
$7.01
Change
-$0.24 (-3.31%)
Updated
May 13 closing price
Capitalization
399.48M
85 days until earnings call
Ad is loading...

EKTAY vs RCEL

Header iconEKTAY vs RCEL Comparison
Open Charts EKTAY vs RCELBanner chart's image
Elekta AB
Price$5.26
Change+$0.09 (+1.74%)
Volume$13.53K
Capitalization3.09B
Avita Medical
Price$7.01
Change-$0.24 (-3.31%)
Volume$498.04K
Capitalization399.48M
EKTAY vs RCEL Comparison Chart
Loading...
EKTAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EKTAY vs. RCEL commentary
May 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EKTAY is a Buy and RCEL is a Hold.

Ad is loading...
COMPARISON
Comparison
May 14, 2025
Stock price -- (EKTAY: $5.26 vs. RCEL: $7.01)
Brand notoriety: EKTAY and RCEL are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: EKTAY: 49% vs. RCEL: 209%
Market capitalization -- EKTAY: $3.09B vs. RCEL: $399.48M
EKTAY [@Medical Specialties] is valued at $3.09B. RCEL’s [@Medical Specialties] market capitalization is $399.48M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EKTAY’s FA Score shows that 1 FA rating(s) are green whileRCEL’s FA Score has 0 green FA rating(s).

  • EKTAY’s FA Score: 1 green, 4 red.
  • RCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, EKTAY is a better buy in the long-term than RCEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EKTAY’s TA Score shows that 6 TA indicator(s) are bullish while RCEL’s TA Score has 5 bullish TA indicator(s).

  • EKTAY’s TA Score: 6 bullish, 2 bearish.
  • RCEL’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, EKTAY is a better buy in the short-term than RCEL.

Price Growth

EKTAY (@Medical Specialties) experienced а +6.80% price change this week, while RCEL (@Medical Specialties) price change was -23.89% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.95%. For the same industry, the average monthly price growth was +5.63%, and the average quarterly price growth was +1.82%.

Reported Earning Dates

RCEL is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Medical Specialties (+1.95% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EKTAY($3.09B) has a higher market cap than RCEL($399M). EKTAY YTD gains are higher at: -5.105 vs. RCEL (-45.234). EKTAY has higher annual earnings (EBITDA): 2.49B vs. RCEL (-33.54M). EKTAY has more cash in the bank: 3.27B vs. RCEL (89.1M). RCEL has less debt than EKTAY: RCEL (42.4M) vs EKTAY (6.67B). EKTAY has higher revenues than RCEL: EKTAY (16.9B) vs RCEL (50.1M).
EKTAYRCELEKTAY / RCEL
Capitalization3.09B399M775%
EBITDA2.49B-33.54M-7,412%
Gain YTD-5.105-45.23411%
P/E Ratio34.01N/A-
Revenue16.9B50.1M33,733%
Total Cash3.27B89.1M3,670%
Total Debt6.67B42.4M15,726%
FUNDAMENTALS RATINGS
EKTAY vs RCEL: Fundamental Ratings
EKTAY
RCEL
OUTLOOK RATING
1..100
1653
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
65
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
69100
PRICE GROWTH RATING
1..100
6087
P/E GROWTH RATING
1..100
68100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EKTAY's Valuation (2) in the null industry is somewhat better than the same rating for RCEL (65). This means that EKTAY’s stock grew somewhat faster than RCEL’s over the last 12 months.

EKTAY's Profit vs Risk Rating (100) in the null industry is in the same range as RCEL (100). This means that EKTAY’s stock grew similarly to RCEL’s over the last 12 months.

EKTAY's SMR Rating (69) in the null industry is in the same range as RCEL (100). This means that EKTAY’s stock grew similarly to RCEL’s over the last 12 months.

EKTAY's Price Growth Rating (60) in the null industry is in the same range as RCEL (87). This means that EKTAY’s stock grew similarly to RCEL’s over the last 12 months.

EKTAY's P/E Growth Rating (68) in the null industry is in the same range as RCEL (100). This means that EKTAY’s stock grew similarly to RCEL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EKTAYRCEL
RSI
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 1 day ago
68%
Bearish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
64%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
66%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 17 days ago
74%
Declines
ODDS (%)
Bearish Trend 8 days ago
62%
Bearish Trend 6 days ago
80%
BollingerBands
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
EKTAY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TSLA334.0715.69
+4.93%
Tesla
BTC.X104169.8100001356.851600
+1.32%
Bitcoin cryptocurrency
GME28.390.34
+1.21%
GameStop Corp
AAPL212.932.14
+1.02%
Apple
SPY586.843.85
+0.66%
SPDR® S&P 500® ETF

EKTAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, EKTAY has been loosely correlated with OSSUY. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EKTAY jumps, then OSSUY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EKTAY
1D Price
Change %
EKTAY100%
+1.74%
OSSUY - EKTAY
44%
Loosely correlated
N/A
PHG - EKTAY
23%
Poorly correlated
+0.27%
RVTY - EKTAY
23%
Poorly correlated
-1.82%
RCEL - EKTAY
23%
Poorly correlated
-3.31%
UTMD - EKTAY
22%
Poorly correlated
+1.28%
More

RCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCEL has been loosely correlated with PHCCF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if RCEL jumps, then PHCCF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCEL
1D Price
Change %
RCEL100%
-3.31%
PHCCF - RCEL
42%
Loosely correlated
N/A
CERS - RCEL
33%
Loosely correlated
-2.96%
VREX - RCEL
33%
Loosely correlated
-0.27%
CVRX - RCEL
33%
Loosely correlated
+14.53%
SGHT - RCEL
32%
Poorly correlated
+6.54%
More